ClinicalTrials.gg
RecruitingNCT06450691FIBRALSUpdated Apr 13, 2026

Modeling Amyotrophic Lateral Sclerosis With Fibroblasts

An interventional study of biopsy in Amyotrophic Lateral Sclerosis, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Amyotrophic Lateral Sclerosis by Assistance Publique - Hôpitaux de Paris — 7 open to participants now, 7 under way, none of them phase 3. Amyotrophic Lateral Sclerosis · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
2nd of 17
110 · median 30
Started
2025
with 1 other
No phase
11 of 21
4 open now
Registered
18th of 21
by date

Among the 21 studies in Amyotrophic Lateral Sclerosis by Assistance Publique - Hôpitaux de Paris, this one is the 2nd largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2025, is one of 11 with no phase, and was the 18th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

7 of the 21 studies in Amyotrophic Lateral Sclerosis by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Amyotrophic Lateral Sclerosis by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Amyotrophic Lateral Sclerosis (ALS) is the most common motor neuron disease in adults. This longitudinal study involves three cohorts of participants: patients with sporadic or hereditary ALS, asymptomatic individuals carrying pathogenic mutations responsible for ALS, and control subjects. In this study, a skin biopsy and blood sampling will be performed at the initial visit (M0), then at M12 (+/- 2 months) for patients, and at M36 (+/- 12 months) for asymptomatic carriers of pathogenic mutations. The aim of this research is to model ALS pathology using fibroblasts derived from the patients' skin biopsies.

Read the detailed description

Amyotrophic Lateral Sclerosis (ALS) is the most common motor neuron disease in adults. This longitudinal study involves three cohorts of participants: patients with sporadic or hereditary ALS, asymptomatic individuals carrying pathogenic mutations responsible for ALS, and control subjects. In this study, a skin biopsy and blood sampling will be performed at the initial visit (M0), then at M12 (+/- 2 months) for patients, and at M36 (+/- 12 months) for asymptomatic carriers of pathogenic mutations. The aim of this research is to model ALS pathology using fibroblasts derived from the patients' skin biopsies.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis

Keywords

  • amyotrophic lateral sclerosis
  • genetic
  • fibroblasts
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adults, both sexes
  • with written consent to participate in the study
  • affiliated to a social security scheme

ALS patients :

  • patients with ALS according to the revised El Escorial criteria :
  • with a hereditary form of ALS, defined by the presence of a family history of ALS or by the demonstration of a pathogenic mutation in the patient or
  • with a juvenile form of the disease, defined by onset of symptoms at less than 30 years of age or
  • with a sporadic form of ALS

Asymptomatic mutation carriers :

- Asymptomatic individuals who carry a mutation causing ALS but have not developed symptoms.

Healthy subjects:

  • control individuals, taking into account male/female and close age matching

Exclusion criteria

Exclusion Criteria:

  • with a known skin disease (acne, atopic dermatitis, psoriasis, melanoma, skin carcinoma, rosacea, scabies; as referenced on http://dermato-info.fr/), which in the investigator's opinion constitutes a to skin
  • have a count of less than 75,000/mm3 in a laboratory test less than 3 months old,
  • with a proven allergy to lidocaine or prilocaine,
  • Pregnant or breast-feeding women, or subjects under guardianship, curatorship or safeguard of justice.
  • Patient's condition which, in the opinion of the investigator, is incompatible with skin sampling or participation in the study.
  • Participation in a clinical trial (involving a drug) or other interventional research if this interferes with FIBRALS research.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    participants (SLA, healthy controls and asymptomatics)

    Patients fulfilling the El Escorial criteria definite ALS or asymptomatics or Healthy controls

    Procedure: biopsy

Interventions

  • Procedurebiopsy

    skin biopsy and blood sampling

06

What researchers measure

Primary outcomes

  1. Detection of cytoplasmic TDP-43, TIA1 and/or p62 aggregates in patient fibroblasts

    Detection of cytoplasmic TDP-43, TIA1 and/or p62 aggregates in patient fibroblasts subjected to various cellular stresses by immunofluorescence analysis.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Sep 2034, 109 months after the start.

Of 134 non-industry interventional studies with no phase under Amyotrophic Lateral Sclerosis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 109 months is above that.

Counting every sponsor, half of 154 studies reached it within 35 months; a quarter within 23 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2024
First posted
Jun 10, 2024
StartActual
Aug 28, 2025
Primary completionEst.
Sep 2034
CompletionEst.
Sep 2034
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06450691
Responsible party
Sponsor
First posted
Jun 10, 2024
Start date
Aug 28, 2025
Primary completion
Sep 2034 (estimated)
Completion
Sep 2034 (estimated)
Last update
Apr 13, 2026

Study contacts

Maria del Mar Amador, MD
Contact
mariadelmar.amador@aphp.fr
33142162472 ext. 33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion